Cellular Dynamics Announces Agreement with AstraZeneca on Use of iPSC-derived Human Cells in Drug Discovery Research

Cellular Dynamics Announces Agreement with AstraZeneca on Use of iPSC-derived
                    Human Cells in Drug Discovery Research

PR Newswire

MADISON, Wis., Jan. 3, 2013

MADISON, Wis., Jan. 3, 2013 /PRNewswire/ -- Cellular Dynamics International,
Inc. (CDI) today announced a Center of Excellence agreement with AstraZeneca
to accelerate the pace of drug discovery through the use of human induced
pluripotent stem cell (iPSC) lines and tissue cells.

iPSC technology, based on reprogramming adult cells from a simple blood sample
or a skin biopsy to a pluripotent stem cell state, shows promise in delivering
robust human cell models of high utility in drug discovery and without the
ethical concerns linked to the use of human embryonic stem cells.

Steve Rees, VP Screening Sciences & Sample Management, Discovery Sciences at
AstraZeneca, said, "This agreement with Cellular Dynamics enables AstraZeneca
to access world-leading expertise in stem cell technology so that we can
better test potential new medicines for safety and efficacy."

Bob Palay, chief executive officer of CDI, said, "This is the third Center of
Excellence agreement we have entered into with a global pharma company, and
these partnerships show customer recognition that leveraging CDI's technical
expertise and resources can help accelerate their discoveries. We are excited
that AstraZeneca shares our vision that iPSC technology can be transformative.
The Center of Excellence agreements show CDI's leadership in developing best
practices to employ human iPSCs to advance healthcare discoveries."

Chris Parker, CDI chief commercial officer, continued, "Increasingly customers
are recognizing CDI's focus and investment on industrializing the manufacture
of iPSC-derived cells. Utilizing these standardized cellular tools enables
customers like AstraZeneca to concentrate on developing therapies rather than
manufacturing cell types."

Under the terms of the Center of Excellence agreement, AstraZeneca will take
advantage of commercially available iCell® products and CDI's recently
launched MyCell™ Products for iPSC reprogramming and differentiation, and the
two parties will collaborate on the development of one or more novel cell
type(s). AstraZeneca will purchase CDI's commercially available iCell
products, including iCell Cardiomyocytes, iCell Neurons, iCell Endothelial
Cells, and iCell Hepatocytes, for use in their safety, discovery, and
regenerative medicine programs. Further, AstraZeneca will rely on CDI's novel
MyCell Products to genetically engineer and manufacture cells from specific
patient groups for use as in vitro disease models. In addition, CDI will work
in partnership with AstraZeneca toward development of new iPSC-derived cell
type(s) to enable novel discovery screening applications. Financial terms of
the agreement were undisclosed.

About Cellular Dynamics International, Inc.
Cellular Dynamics International, Inc. (CDI) is a leading developer of
next-generation stem cell technologies for drug development, cell therapy,
tissue engineering and organ regeneration. CDI harnesses its unique
manufacturing technology to produce differentiated tissue cells from any
individual's stem cell line in industrial quality, quantity and purity. CDI is
accelerating the adoption of pluripotent stem cell technology, adapting its
methods to fit into standard clinical practice by the creation of individual
stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr.
James Thomson, a pioneer in human pluripotent stem cell research at the
University of Wisconsin-Madison. CDI's facilities are located in Madison,
Wisconsin. See www.cellulardynamics.com.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a
primary focus on the discovery, development and commercialisation of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:
www.astrazeneca.com

SOURCE Cellular Dynamics International, Inc.

Website: http://www.cellulardynamics.com
Contact: Joleen Rau, Senior Director, Marketing & Communications, Cellular
Dynamics International, Inc., +1-608-310-5142, jrau@cellulardynamics.com; or
Robert E. Flamm, Ph.D., +1-212-845-4226, robert.flamm@russopartnersllc.com, or
Tony Russo, +1-212-845-4251, tony.russo@russopartnersllc.com, both of Russo
Partners LLC; or Laura Woodin, R&D Media Lead, AstraZeneca, +1-302-885-1087,
Laura.Woodin@astrazeneca.com
 
Press spacebar to pause and continue. Press esc to stop.